Current and future therapies for treating chronic spontaneous urticaria

References

• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–887.
   PubMed Web of Science ®Google Scholar
• Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66:317–330.
   PubMed Web of Science ®Google Scholar
• O’Donnell BF. Urticaria: impact on quality of life and economic cost. Immunol Allergy Clin North Am. 2014;34:89–104.
   PubMed Web of Science ®Google Scholar
• Broder MS, Raimundo K, Antonova E, et al. Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria. Am J Clin Dermatol. 2015;16:313–321.
   PubMed Web of Science ®Google Scholar
• Vietri J, Turner SJ, Tian H, et al. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. Ann Allergy Asthma Immunol. 2015;115:306–311.
   PubMed Web of Science ®Google Scholar
• Balp MM, Vietri J, Tian H, et al. The impact of chronic urticaria from the patient’s perspective: a survey in five European countries. Patient. 2015;8:551–558.
   PubMedGoogle Scholar
• Rabelo-Filardi R, Daltro-Oliveira R, Campos RA. Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol. 2013;161:197–204.
   PubMed Web of Science ®Google Scholar
• Kröpfl L, Maurer M, Zuberbier T. Treatment strategies in urticaria. Expert Opin Pharmacother. 2010;11:1445–1450.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64:1417–1426.
   PubMed Web of Science ®Google Scholar
• Cugno M, Asero R, Tedeschi A, et al. Inflammation and coagulation in urticaria and angioedema. Curr Vasc Pharmacol. 2012;10:653–658.
   PubMed Web of Science ®Google Scholar
• Altman K, Chang C. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clin Rev Allergy Immunol. 2013;45:47–62.
   PubMed Web of Science ®Google Scholar
• Jain S. Pathogenesis of chronic urticaria: an overview. Dermatol Res Pract. 2014;2014:674709.
   PubMedGoogle Scholar
• Ferrer M. Immunological events in chronic spontaneous urticaria. Clin Transl Allergy. 2015;5:30.
   PubMedGoogle Scholar
• Kasperska-Zajac A. Acute-phase response in chronic urticaria. J Eur Acad Dermatol Venereol. 2012;26:665–672.
   PubMed Web of Science ®Google Scholar
• Ventura MT, Cassano N, Romita P, et al. Management of chronic spontaneous urticaria in the elderly. Drugs Aging. 2015;32:271–282.
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008;1:145–155.
   PubMedGoogle Scholar
• Vena GA, Cassano N, Buquicchio R, et al. Antiinflammatory effects of H1-antihistamines: clinical and immunological relevance. Curr Pharm Des. 2008;14:2902–2911.
   PubMed Web of Science ®Google Scholar
• Kavosh ER, Khan DA. Second-generation H1-antihistamines in chronic urticaria: an evidence-based review. Am J Clin Dermatol. 2011;12:361–376.
   PubMed Web of Science ®Google Scholar
• Weller K, Ardelean E, Scholz E, et al. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol. 2013;93:168–174.
   PubMed Web of Science ®Google Scholar
• Weller K, Viehmann K, Bräutigam M, et al. Management of chronic spontaneous urticaria in real life–in accordance with the guidelines? A cross-sectional physician-based survey study. J Eur Acad Dermatol Venereol. 2013;27:43–50.
   PubMed Web of Science ®Google Scholar
• Staevska M, Gugutkova M, Lazarova C, et al. Night-time sedating H1-antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol. 2014;171:148–154.
   PubMed Web of Science ®Google Scholar
• Weller K, Ziege C, Staubach P, et al. H1-antihistamine up-dosing in chronic spontaneous urticaria: patients’ perspective of effectiveness and side effects–a retrospective survey study. PLoS One. 2011;6:e23931.
   PubMed Web of Science ®Google Scholar
• Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing? J Investig Allergol Clin Immunol. 2013;23:141–144.
   PubMed Web of Science ®Google Scholar
• Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy ClinImmunol. 2010;125:676–682.
   PubMed Web of Science ®Google Scholar
• Giménez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol. 2009;23:1088–1091.
   PubMed Web of Science ®Google Scholar
• Dubertret L, Zalupca L, Cristoroulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Eur J Dermatol. 2007;17:223–228.
   PubMed Web of Science ®Google Scholar
• Magen E, Mishal J, Zeldin Y, et al. Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria. Allergy Asthma Proc. 2011;32:460–466.
   PubMed Web of Science ®Google Scholar
• Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135:337–342.
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1-antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2014;2014:2–28.
   Google Scholar
• Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–935.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101–109.
   PubMed Web of Science ®Google Scholar
• Urgert MC, van den Elzen MT, Knulst AC, et al. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol. 2015;173:404–415.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137:474–481.
   PubMed Web of Science ®Google Scholar
• Metz M, Ohanyan T, Church MK, et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73:57–62.
   PubMed Web of Science ®Google Scholar
• Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria. Ann Allergy Asthma Immunol. 2015;115:126–129.
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Valero A, Velasco M, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther. 2013;13:1225–1228.
   PubMed Web of Science ®Google Scholar
• Metz M, Ohanyan T, Church MK, et al. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150:288.
   PubMed Web of Science ®Google Scholar
• Khan DA. Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. J Allergy Clin Immunol Pract. 2013;1:433–440.
   PubMed Web of Science ®Google Scholar
• Grattan CE, O’Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporine in chronic “idiopathic” urticaria. Br J Dermatol. 2000;143:365–372.
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Colombo D, et al. Cyclosporin A in chronic idiopathic urticaria: a double blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;55:705–709.
   PubMed Web of Science ®Google Scholar
• Asero R, Tedeschi A, Cugno M. Treatment of refractory chronic urticaria: current and future therapeutic options. Am J Clin Dermatol. 2013;14:481–488.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol. 2004;114:619–625.
   PubMed Web of Science ®Google Scholar
• Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol. 2002;110:484–488.
   PubMed Web of Science ®Google Scholar
• Kosnik M, Subic T. Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria. Respir Med. 2011;105(Suppl 1):S84–S88.
   PubMed Web of Science ®Google Scholar
• Nettis E, Colanardi MC, Paradiso MT, et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2004;34:1401–1407.
   PubMed Web of Science ®Google Scholar
• De Silva NL, Damayanthi H, Rajapakse AC, et al. Leukotriene receptor antagonists for chronic urticaria: a systematic review. Allergy Asthma Clin Immunol. 2014;10:24.
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2012;4:326–331.
   PubMed Web of Science ®Google Scholar
• Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol. 2010;20:386–390.
   PubMed Web of Science ®Google Scholar
• Kim S, Baek S, Shin B, et al. Influence of initial treatment modality on long-term control of chronic idiopathic urticaria. PLoS One. 2013;8:e69345.
   Google Scholar
• Simons FE, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol. 1995;95:685–693.
   PubMed Web of Science ®Google Scholar
• Fedorowicz Z, Van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev. 2012;3:CD008596.
   PubMed Web of Science ®Google Scholar
• Mitchell S, Balp MM, Samuel M, et al. Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first-line treatments. Int J Dermatol. 2015;54:1088–1104.
   PubMed Web of Science ®Google Scholar
• Rorie A, Poole JA. Vitamin D supplementation: a potential booster for urticaria therapy. Expert Rev Clin Immunol. 2014;10:1269–1271.
   PubMed Web of Science ®Google Scholar
• Rasool R, Masoodi KZ, Shera IA, et al. Chronic urticaria merits serum vitamin D evaluation and supplementation; a randomized case control study. World Allergy Organ J. 2015;8:15.
   PubMed Web of Science ®Google Scholar
• Magerl M, Rother M, Bieber T, et al. Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2013;27:e363–369.
   Google Scholar
• Available from: https://clinicaltrials.gov/.
   Google Scholar
• Gauvreau GM, Harris JM, Boulet LP, et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med. 2014;6:243ra85.
   PubMed Web of Science ®Google Scholar
• Menzella F, Lusuardi M, Galeone C, et al. Tailored therapy for severe asthma. Multidiscip Respir Med. 2015;10:1.
   PubMed Web of Science ®Google Scholar
• Holgate ST. New strategies with anti-IgE in allergic diseases. World Allergy Organ J. 2014;7:17.
   PubMedGoogle Scholar
• Ehlers I, Henz BM, Zuberbier T. Diagnose und Therapie pseudoallergischer Reaktionen der Haut auf Nahrungsmittel. Allergologie. 1996;6:270–276.
   Google Scholar
• Zuberbier T, Czarnetzki BM. High response rate to additive-free diet in chronic urticaria. Br J Dermatol. 1996;134:1151–1164.
   Web of Science ®Google Scholar
• McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015;519:237–241.
   PubMed Web of Science ®Google Scholar